Investor Profile: Medicxi — Thesis, Cheque Size & How to Apply

Building a therapeutics company and wondering how to get funding from Medicxi? Founded in 2016 as a spinout of Index Ventures' life-sciences team and headquartered in London, Medicxi is a healthcare-focused investment firm creating and investing in companies across the full drug-development continuum. Medicxi funding now spans over €2 billion across six funds, including Fund V at €500M (November 2025). Its signature is the 'asset-centric' model: capital-efficient investing around a single product vision addressing clear unmet medical need.

Thesis and sweet spot

Medicxi invests in early and late-stage therapeutics with a product vision aimed at clear unmet medical need, using a capital-efficient asset-centric approach — funding the asset, not the overhead. Strategic pharma limited partners including GSK, Johnson & Johnson (JJDC), Novartis and Verily back the funds, notably with no preferential rights over portfolio companies — the pharma LPs provide insight and validation without strings on exits.

The sweet spot is therapeutics companies — from discovery through late-stage development — where a focused, well-capitalised asset plan can reach value inflection efficiently. With offices in London, Geneva and Jersey, the firm operates across the European and US biotech ecosystems.

Cheque size and fund

Medicxi has raised over €2.0B across six funds in ten years: Medicxi Ventures 1 (€210M, 2016), Medicxi Growth 1 ($300M, 2017), a €200M Secondary Fund (2020) and Fund V (€500M, November 2025). The firm does not state a general cheque-size range; the one public data point is fund-specific — Medicxi Growth 1 made €10-€25M equity investments per 2017 coverage — so founders should discuss sizing directly.

Notable portfolio

The portfolio includes standout European biotech outcomes: Vicebio (acquired by Sanofi for $1.6B), Ethyreal Bio ($101M financing), Centessa Pharmaceuticals, RAPT Therapeutics, Merus, ProfoundBio, Genmab, PanGenetics (sold to AbbVie), Molecular Partners, XO1 (sold to Janssen), Curevo, Acera Therapeutics, T-CypherBio and Petalion Therapeutics. The Vicebio exit is the flagship validation of the asset-centric model.

Partners

The firm was co-founded by partners Francesco De Rubertis and Giovanni Mariggi, alongside partners Nick Williams and Shyam Masrani. Founding general partners from the 2016 launch include David Grainger, Kevin Johnson and Michèle Ollier — the Index Ventures life-sciences team that seeded the firm.

Programs, credits and perks

Medicxi does not run a public accelerator or credits programme. Its value-add is structural: the asset-centric model itself, pharma-LP insight without preferential rights, and a partnership that has repeatedly built therapeutics companies from idea to acquisition.

How to apply for funding

Medicxi does not publish a pitch email or application form — its listed contacts are for press only. Therapeutics founders typically reach the team through biotech-network introductions. A pitch built around a single asset with a clear unmet-need thesis and a capital-efficient development plan speaks the firm's language.